title: Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.
abstract: BACKGROUND
  In phase-3 clinical trials, the interleukin (IL-1) blocker, rilonacept (IL-1 Trap), demonstrated efficacy for gout flare prevention during initiation of urate-lowering therapy. This trial evaluated rilonacept added to a standard-of-care, indomethacin, for treatment of acute gout flares.
  
  
  METHODS
  Adults, aged 18-70 years, with gout presenting within 48 hours of flare onset and having at least moderate pain as well as swelling and tenderness in the index joint were randomized to subcutaneous (SC) rilonacept 320 mg at baseline plus oral indomethacin 50 mg TID for 3 days followed by 25 mg TID for up to 9 days (n = 74); SC placebo at baseline plus oral indomethacin as above (n=76); or SC rilonacept 320 mg at baseline plus oral placebo (n=75). The primary efficacy endpoint was change in pain in the index joint (patient-reported using a Likert scale (0=none; 4=extreme)) from baseline to the average of values at 24, 48 and 72 hours (composite time point) for rilonacept plus indomethacin versus indomethacin alone. Comparison of rilonacept monotherapy with indomethacin monotherapy was dependent on demonstration of significance for the primary endpoint. Safety evaluation included clinical laboratory and adverse event (AE) assessments.
  
  
  RESULTS
  Patient characteristics were comparable among the groups; the population was predominantly male (94.1%), white (75.7%), with mean±SD age of 50.3±10.6 years. All treatment groups reported within-group pain reductions from baseline (P<0.0001). Although primary endpoint pain reduction was greater with rilonacept plus indomethacin (-1.55±0.92) relative to indomethacin alone (-1.40±0.96), the difference was not statistically significant (P=0.33), so formal comparison between monotherapy groups was not performed. Pain reduction over the 72-hour period with rilonacept alone (-0.69±0.97) was less than that in the other groups, but pain reduction was similar among groups at 72 hours. Treatment with rilonacept was well-tolerated with no reported serious AEs related to rilonacept. Across all groups, the most frequent AEs were headache and dizziness.
  
  
  CONCLUSIONS
  Although generally well-tolerated, rilonacept in combination with indomethacin and rilonacept alone did not provide additional pain relief over 72 hours relative to indomethacin alone in patients with acute gout flare.
  
  
  BACKGROUND
  ClinicalTrials.gov registration number NCT00855920.
authors: Robert A
authors: RA
authors: Terkeltaub
authors: H Ralph
authors: HR
authors: Schumacher
authors: John D
authors: JD
authors: Carter
authors: Herbert S B
authors: HS
authors: Baraf
authors: Robert R
authors: RR
authors: Evans
authors: Jian
authors: J
authors: Wang
authors: Shirletta
authors: S
authors: King-Davis
authors: Steven P
authors: SP
authors: Weinstein
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015210:Arthritis, Gouty / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006074:Gout Suppressants; D011993:Recombinant Fusion Proteins; C531377:rilonacept; D007213:Indomethacin
references: Drugs Aging. 2007;24(1):21-36
references: 17233545
references: Arthritis Rheum. 2004 Aug;50(8):2400-14
references: 15334451
references: Semin Arthritis Rheum. 2009 Jun;38(6):411-9
references: 18973929
references: Arthritis Res Ther. 2007;9(2):R28
references: 17352828
references: Cleve Clin J Med. 2008 Jul;75 Suppl 5:S22-5
references: 18819330
references: J Clin Rheumatol. 2009 Oct;15(7):366
references: 20009976
references: Nephron. 1976;16(1):31-41
references: 1244564
references: Nat Med. 2003 Jan;9(1):47-52
references: 12483208
references: BMJ. 2011 Jan 11;342:c7086
references: 21224324
references: J Rheumatol. 1994 Jul;21(7):1325-7
references: 7966077
references: Lancet. 2008 May 31;371(9627):1854-60
references: 18514729
references: Br J Clin Pharmacol. 1987 Jul;24(1):33-6
references: 3304384
references: Ann Rheum Dis. 2006 Oct;65(10):1312-24
references: 16707532
references: Arthritis Rheum. 1977 Apr;20(3):895-900
references: 856219
references: Nature. 2006 Mar 9;440(7081):237-41
references: 16407889
references: J Med Econ. 2011;14(1):10-5
references: 21138339
references: Ann Rheum Dis. 2009 Oct;68(10):1602-8
references: 19528034
references: Arthritis Res Ther. 2009;11(4):236
references: 19664185
references: Pharmacol Ther. 2008 Feb;117(2):244-79
references: 18155297
references: J Rheumatol. 1993 Jan;20(1):111-3
references: 8441139
references: Semin Arthritis Rheum. 2011 Jun;40(6):501-11
references: 20828793
references: Am J Med. 2011 Feb;124(2):155-63
references: 21295195
references: BMJ. 2002 Jun 22;324(7352):1488-92
references: 12077033
references: Arthritis Rheum. 2010 Apr;62(4):1060-8
references: 20131255
references: Arthritis Res Ther. 2010;12(6):223
references: 21205285
references: Value Health. 2007 Jul-Aug;10(4):231-7
references: 17645677
references: Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):567-72
references: 19822073
references: Arthritis Rheum. 2004 Feb;50(2):598-606
references: 14872504
references: Arthritis Rheum. 2009 Sep 15;61(9):1268-70
references: 19714614
references: Arthritis Rheum. 2012 Mar;64(3):876-84
references: 22223180
references: J Manag Care Pharm. 2008 Mar;14(2):164-75
references: 18331118
references: Ann Emerg Med. 2007 May;49(5):670-7
references: 17276548
references: Arthritis Res Ther. 2010;12(2):R63
references: 20370912
references: Arthritis Rheum. 2010 Jun;62(6):1592-601
references: 20178131
references: Arthritis Rheum. 2009 Dec;60(12):3642-50
references: 19950258
references: Arthritis Res Ther. 2011 Mar 25;13(2):R53
references: 21439048
references: Curr Med Res Opin. 2010 Dec;26(12):2813-21
references: 21050059
references: Arthritis Rheum. 2006 Feb;54(2):383-6
references: 16447213
references: Arthritis Care Res (Hoboken). 2012 Oct;64(10):1462-70
references: 22549879
references: Arthritis Rheum. 2010 Oct;62(10):3064-76
references: 20533546
references: Ann Rheum Dis. 2007 Dec;66(12):1683-4
references: 17998217
references: Am J Ther. 2012 Nov;19(6):e157-66
references: 21317625